|Bid||144.20 x 100|
|Ask||144.45 x 100|
|Day's Range||142.16 - 144.85|
|52 Week Range||71.46 - 167.86|
|PE Ratio (TTM)||186.55|
|Earnings Date||Feb 7, 2018 - Feb 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||182.58|
NEW YORK, NY / ACCESSWIRE / December 14, 2017 / Teva shares sank almost 5% yesterday after traders showed concern over calls for protest in Israel over the company planning on cutting thousands of jobs ...
The annual meeting of the American Society of Hematology was the key highlight this week with several companies like bluebird (BLUE) presenting data on their investigational treatments.
With a market capitalization of $35.83B, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) falls in the category of stocks popularly identified as large-caps. These are established companies that attract investors due to diversifiedRead More...
Deutsche Bank said "chances of a Vertex takeout are as good as at any point in the company's history."
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG today announced that the companies will co-develop and co-commercialize CTX001, an investigational gene editing treatment, as part of the companies’ previously announced collaboration aimed at the discovery and development of new gene editing treatments that use the CRISPR/Cas9 technology.
CEO & President of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Jeffrey M Leiden sold 125,000 shares of VRTX on 12/11/2017 at an average price of $141.35 a share.
Twenty-one analysts are tracking Alexion Pharmaceuticals in December 2017. Six of them are recommending a “strong buy,” while 12 are recommending a “buy.”
Biotech mergers and acquisitions, which were quite lean in 2017, may pick up significantly in 2018 if the proposed tax reforms are finally approved.
Vertex Pharmaceuticals' (VRTX) phase III study evaluating Kalydeco in children as young as one year meets its primary safety endpoint.
Beleaguered biotech investors will likely have to wait until 2018 to get some much-needed relief, analysts say.
Vertex Pharmaceuticals Incorporated today announced positive results from an open-label Phase 3 study of KALYDECO® in children with cystic fibrosis ages 1 to 2 years who have one of 10 mutations in the cystic fibrosis transmembrane conductance regulator gene.
In October 2017, Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that their Phase 3 dupilumab study had met its primary and secondary endpoints. The study was conducted to evaluate the safety ...
Galapagos stock popped Monday to Vertex's detriment after figuring out one piece of its cystic fibrosis puzzle.
After rising 15.4% in the first nine months of the year, the Medical-Biotech /Genetics industry has declined 13.4% so far in the fourth quarter.